Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could drug holidays ease fatigue in advanced prostate cancer?

NCT ID NCT07216248

Recruiting now Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 08, 2026 · Updated 29 times

Summary

This study tests whether men with metastatic hormone-sensitive prostate cancer who have a very low PSA can safely take breaks from hormone therapy (relugolix) to reduce fatigue. Half the participants will take the drug continuously, the other half will take breaks. The study will compare fatigue levels and how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huntsman Cancer Institute at University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)